About Kineticos Ventures
Kineticos Ventures’ portfolio of investments is made up of biotechs striving to disrupt how drugs are developed, diseases are diagnosed, and patients are treated. The Kineticos Ventures fund focuses on significant, unmet medical needs in antimicrobial resistance (AMR), oncology, neurosciences, and rare diseases.
Kineticos will support early-stage AMR businesses with founders who have created unique, innovative, and know-how-protected products and services. We seek companies focused on therapeutics, diagnostics, and novel anti-microbial and anti-fungal technologies.
In addition to targeting these disease states with patients in need, we look for biotechs utilizing disruptive technologies such as cell and gene therapy, gene editing, and mRNA/RNAi, all technologies dramatically changing how medicine is practiced.
To learn more about Kineticos Ventures, you can reach us at email@example.com
Funding Coupled with Execution Build Lasting Biotechs
While financial resources are essential for the growth of emerging biotechs, the addition of in-depth industry knowledge, industry relationships, a community of advisors, and thoughtful execution are critical for these young companies to succeed.
Kineticos Ventures forms comprehensive relationships and is thoroughly involved in the effort to help companies grow and develop—early funding is just the beginning.
Kineticos Ventures Criteria
We seek portfolio companies possessing characteristics critical for success
The ability to recruit best-in-class scientists and entrepreneurial business leaders
Disruptive technologies with high potential ROI
Unmet needs in AMR, oncology, neurosciences, and rare diseases
Ample intellectual property protections for platform technologies
Viable, accessible commercial market with ample reimbursement
Clear regulatory path for pre-clinical, clinical, and CMC development